Eli Lilly is paying $140 million for the exclusive right to buy Radionetics Oncology for the price of $1 billion. The clinical-stage startup, a Crinetics Pharmaceuticals spinout, develops radiopharmaceuticals that target GPCRs overexpressed by solid tumors.
The post Eli Lilly Puts $1B on the Line to Expand its Cancer Radiopharmaceuticals Prospects appeared first on MedCity News.
